ZA93422B - Oligonucleotide analogs, their preparation and use - Google Patents

Oligonucleotide analogs, their preparation and use

Info

Publication number
ZA93422B
ZA93422B ZA93422A ZA93422A ZA93422B ZA 93422 B ZA93422 B ZA 93422B ZA 93422 A ZA93422 A ZA 93422A ZA 93422 A ZA93422 A ZA 93422A ZA 93422 B ZA93422 B ZA 93422B
Authority
ZA
South Africa
Prior art keywords
aryl
alkyl
preparation
seh
alkoxy
Prior art date
Application number
ZA93422A
Other languages
English (en)
Inventor
Eugen Uhlmann
Gerard O'malley
Irvin Winkler
Anuschirwan Peyman
Matthias Helsberg
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA93422B publication Critical patent/ZA93422B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ZA93422A 1992-01-22 1993-01-21 Oligonucleotide analogs, their preparation and use ZA93422B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4201662 1992-01-22

Publications (1)

Publication Number Publication Date
ZA93422B true ZA93422B (en) 1993-09-16

Family

ID=6450030

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA93422A ZA93422B (en) 1992-01-22 1993-01-21 Oligonucleotide analogs, their preparation and use

Country Status (17)

Country Link
EP (1) EP0552766B1 (fr)
JP (1) JP3717081B2 (fr)
KR (1) KR930016437A (fr)
AT (1) ATE217880T1 (fr)
AU (1) AU661365B2 (fr)
CA (1) CA2087818C (fr)
DE (1) DE59310285D1 (fr)
DK (1) DK0552766T3 (fr)
ES (1) ES2177532T3 (fr)
FI (1) FI115214B (fr)
HU (1) HU227794B1 (fr)
IL (1) IL104461A (fr)
NO (1) NO308215B1 (fr)
NZ (1) NZ245720A (fr)
PL (1) PL172257B1 (fr)
PT (1) PT552766E (fr)
ZA (1) ZA93422B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
ES2103408T3 (es) * 1992-09-24 1997-09-16 Hoechst Ag Analogos de oligorribonucleotidos y ribozimas con uniones terminales en 3'-3' o 5'-5' respectivamente.
EP0602524A1 (fr) * 1992-12-15 1994-06-22 Hoechst Aktiengesellschaft Sondes marqués par chemiluminescence et leur utilisation dans épreuves des sondes
US6087491A (en) * 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
WO1994015946A1 (fr) * 1993-01-08 1994-07-21 Hybridon, Inc. Synthese de blocs dimeres et leur utilisation pour l'assemblage d'oligonucleotides
ES2086997T3 (es) * 1993-01-25 1996-07-01 Hybridon Inc Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
CA2114355A1 (fr) * 1993-01-29 1994-07-30 Hidehiko Furukawa Oligodesoxyribonucleotides modifies, leur preparation et leur utilisation therapeutique
US5532130A (en) * 1993-07-20 1996-07-02 Dyad Pharmaceutical Corporation Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE4408528A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
US6919441B2 (en) 1994-03-14 2005-07-19 Aventis Pharma Deutschland Gmbh Polyamide-oligonucleotide derivatives, their preparation and use
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
HUT76094A (en) * 1994-03-18 1997-06-30 Lynx Therapeutics Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
DE4415370A1 (de) * 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US5986076A (en) * 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
DE4438918A1 (de) * 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US6150510A (en) * 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
EP0739898B1 (fr) * 1995-03-13 2001-09-26 Aventis Pharma Deutschland GmbH Phosphonomonoester acides nucléiques, leur préparation et leur utilisation
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US5684143A (en) * 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) * 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
GB9606158D0 (en) * 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
DK0808898T3 (da) * 1996-05-24 2004-09-27 Aventis Pharma Gmbh Reagens og fremgangsmåde til inhibering af N-ras-ekspression
DE19627898A1 (de) * 1996-07-11 1998-01-15 Hoechst Ag Festphasensynthese von Oligonucleotiden
HUP0100044A3 (en) * 1997-05-05 2003-08-28 Sanofi Aventis Deutschland Modified antisense nucleotides complementary to a section of the human ha-ras gene
AU9460898A (en) * 1997-10-14 1999-05-03 Sankyo Company Limited Modified oligodeoxyribonucleotides having tggg sequence
EP1004661A1 (fr) 1998-11-11 2000-05-31 DALLI-WERKE WÄSCHE- und KÖRPERPFLEGE GmbH & Co. KG Granulé de haute densité, procédé pour sa production, son utilisation en tant que désintégrant pour tablettes
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
DE19935302A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen
DE10133915A1 (de) 2001-07-12 2003-02-06 Aventis Pharma Gmbh Neue Oligoribonucleotid-Derivate zur gezielten Hemmung der Genexpression
EP1660657A1 (fr) 2003-08-28 2006-05-31 Novartis AG Double helice d'arn d'interference possedant des extremites franches et des modifications en 3'
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US10131904B2 (en) 2008-02-11 2018-11-20 Rxi Pharmaceuticals Corporation Modified RNAi polynucleotides and uses thereof
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
US10138485B2 (en) 2008-09-22 2018-11-27 Rxi Pharmaceuticals Corporation Neutral nanotransporters
WO2010059226A2 (fr) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition de map4k4 via arni
WO2010090762A1 (fr) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Duplexes d'arn avec régions de nucléotide phosphorothioate à brin unique pour fonctionnalité supplémentaire
CA2794187C (fr) 2010-03-24 2020-07-14 Rxi Pharmaceuticals Corporation Arn interferant dans des indications oculaires
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
CN110042099A (zh) 2010-03-24 2019-07-23 菲奥医药公司 皮肤与纤维化症候中的rna干扰
JP6772062B2 (ja) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
WO2015125845A1 (fr) * 2014-02-20 2015-08-27 塩野義製薬株式会社 Modification de site phosphate d'acide nucléique contenant un hétérocycle non aromatique contenant de l'azote
CA2947270A1 (fr) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Procedes de traitement du cancer au moyen d'un acide nucleique deciblage de mdm2 ou mycn
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
EP3319614B1 (fr) 2015-07-06 2020-12-23 Phio Pharmaceuticals Corp. Molécules d'acide nucléique ciblant la superoxyde dismutase 1 (sod1)
WO2017007825A1 (fr) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Procédés pour le traitement de troubles neurologiques à l'aide d'une petite molécule synergique et approche thérapeutique utilisant des acides nucléiques
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
MX2020011570A (es) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3239888A1 (de) * 1982-10-28 1984-05-03 Hubert Prof. Dr. 2000 Hamburg Köster Verfahren zur herstellung von oligonucleosidphosphonaten
US4739044A (en) * 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
WO1988003149A1 (fr) * 1986-10-30 1988-05-05 Daicel Chemical Industries, Ltd. Procede de synthese d'oligonucleotides et composes servant a former des groupes protecteurs a poids moleculaire eleve
US4816571A (en) * 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
DE69034150T2 (de) * 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-Modifizierte Oligonukleotide
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
GB9021625D0 (en) * 1990-10-04 1990-11-21 Ici Plc Synthesis of oligonucleotides

Also Published As

Publication number Publication date
HU227794B1 (en) 2012-03-28
KR930016437A (ko) 1993-08-26
PT552766E (pt) 2002-10-31
NO930199D0 (no) 1993-01-21
NO308215B1 (no) 2000-08-14
CA2087818C (fr) 2007-07-10
JP3717081B2 (ja) 2005-11-16
HU9300162D0 (en) 1993-04-28
DE59310285D1 (de) 2002-06-27
EP0552766A2 (fr) 1993-07-28
NO930199L (no) 1993-07-23
AU661365B2 (en) 1995-07-20
PL297515A1 (en) 1993-09-06
AU3191093A (en) 1993-07-29
ES2177532T3 (es) 2002-12-16
ATE217880T1 (de) 2002-06-15
FI930220A0 (fi) 1993-01-20
DK0552766T3 (da) 2002-08-19
PL172257B1 (pl) 1997-08-29
CA2087818A1 (fr) 1993-07-23
HUT63173A (en) 1993-07-28
EP0552766B1 (fr) 2002-05-22
IL104461A0 (en) 1993-05-13
NZ245720A (en) 1995-12-21
EP0552766A3 (en) 1994-09-07
JPH05310779A (ja) 1993-11-22
IL104461A (en) 2001-05-20
FI930220A (fi) 1993-07-23
FI115214B (fi) 2005-03-31

Similar Documents

Publication Publication Date Title
IL104461A0 (en) Oligonucleotide analogs,their preparation and use
Sinha et al. β-Cyanoethyl N, N-dialkylamino/N-morpholinomonochloro phosphoamidites, new phosphitylating agents facilitating ease of deprotection and work-up of synthesized oligonucleotides
US5773571A (en) Peptide nucleic acids
DE69415343T2 (de) 2'-amido-und 2'-peptido-modifizierte oligonukleotide
ATE199725T1 (de) Synthetische katalytische oligonukleotide
JP2008253251A (ja) 核酸類縁体並びに診断薬および分析方法におけるその使用方法
PT982398E (pt) Acidos nucleicos e suas utilizacoes no teste de beta-lactamase
ATE374833T1 (de) Verfahren zur synthese von nukleinsäuren
FI951132A (fi) Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö
US20050277138A1 (en) Reactive functional groups
CN1281762C (zh) 非特异杂交抑制剂、临床诊断试剂和临床分析方法
ATE55109T1 (de) Chemisches verfahren zur herstellung von abkoemmlingen von oxamid.
DE69501705T2 (de) Verfahren zur Herstellung von optisch aktiven Piperazinderivaten und Zwischenprodukten für ihre Herstellung
JPS63246393A (ja) オリゴヌクレオチド誘導体
RU92001266A (ru) Способ получения нерадиоактивномеченого зонда для определения нуклеотидных последовательностей